Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Werewolf Therapeutics, Inc.

NASDAQ: HOWL · Life Sciences · 2 alerts · CIK 1785530

Share price
$0.9908Close, Nov 16
Market cap
$48.2M
Shares outstanding
48.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Werewolf Therapeutics, Inc. filings on SEC EDGAR ↗

9:23 AM ET 8-K
Clinical Trial Data

Werewolf Therapeutics Clinical Trial Data

Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330 for the treatment of solid tumors at the SITC 2026 Annual Meeting. WTX-124 demonstrated durable antitumor activity, including a complete response in a patient with cutaneous squamous cell carcinoma, and the company aligned with the FDA on a recommended Phase 2 dose of 18 mg. WTX-330 was reported as well-tolerated with evidence of monotherapy clinical activity in advanced, treatment-refractory disease.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.